Literature DB >> 8897568

Influence of enalapril on experimental cyclosporin A nephrotoxicity.

A Anarat1, A Noyan, G Gonlusen, N Duman, D Tuncer.   

Abstract

The purpose of this study was to investigate if enalapril could be administered with cyclosporin A (CyA) to reduce its nephrotoxicity. Sixty rats were divided into five groups: group I, Control group; group II, rat treated with oral enalapril; group III, rats treated with CyA: group IV, rats treated with CyA and enalapril; group V, rats treated with enalapril before the CyA therapy. At the end of the therapy mean serum creatinine concentrations were not statistically different between the groups (P > 0.05), in groups treated with CyA there were no statistically significant differences between mean CyA levels (P > 0.05), and mean blood urea nitrogen levels of the groups treated with CyA were significantly elevated (P < 0.05) compared with groups not treated with CyA. Morphologically acute CyA nephrotoxicity was evaluated by the following features: (1) tubular vacuolization, (2) tubular necrosis, (3) tubular microcalcification, and (4) peritubular capillary congestion. These lesions were scored semiquantitatively on a scale from 0 to 4+. The most common tubular pathology was tubular vacuolization, which was more severe in groups III and IV. Tubular necrosis was most severe in group III. In conclusion, enalapril seems to suppress the severest form of CyA nephrotoxicity, namely tubular necrosis, if administered prior to CyA treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897568     DOI: 10.1007/s004670050173

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease.

Authors:  H Trachtman; B Gauthier
Journal:  J Pediatr       Date:  1988-02       Impact factor: 4.406

2.  Effect of captopril in nephrotic-range proteinuria due to renovascular hypertension.

Authors:  A Martinez Vea; C García Ruiz; M Carrera; J A Oliver; C Richart
Journal:  Nephron       Date:  1987       Impact factor: 2.847

3.  Morphological patterns in cyclosporine-treated renal transplant recipients.

Authors:  M J Mihatsch; G Thiel; V Basler; B Ryffel; J Landmann; J von Overbeck; H U Zollinger
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

Review 4.  Cyclosporine in nephrotic syndrome.

Authors:  C Ponticelli; E Rivolta
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

5.  Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.

Authors:  B M Murray; R C Venuto; R Kohli; E E Cunningham
Journal:  Am J Kidney Dis       Date:  1990-07       Impact factor: 8.860

6.  Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity.

Authors:  E J Barros; M A Boim; H Ajzen; O L Ramos; N Schor
Journal:  Kidney Int       Date:  1987-07       Impact factor: 10.612

7.  Nephrotoxicity of cyclosporine in spontaneously hypertensive rats: effects on blood pressure and vascular lesions.

Authors:  B Ryffel; H Siegl; R Petric; A M Muller; R Hauser; M J Mihatsch
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

Review 8.  Mechanism of action of cyclosporin A and rationale for use in nephrotic syndrome.

Authors:  J F Borel
Journal:  Clin Nephrol       Date:  1991       Impact factor: 0.975

9.  Renal protective effect of long term antihypertensive therapy with enalapril.

Authors:  J H Bauer; G P Reams
Journal:  Drugs       Date:  1988       Impact factor: 9.546

10.  Morphology of cyclosporine nephrotoxicity in the rat.

Authors:  M J Mihatsch; B Ryffel; M Hermle; F P Brunner; G Thiel
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

View more
  3 in total

1.  Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.

Authors:  Jee Min Park; Sung Chul Won; Jae Il Shin; Hyunee Yim; Ki Soo Pai
Journal:  Pediatr Nephrol       Date:  2010-12-24       Impact factor: 3.714

2.  Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis.

Authors:  Jaana Ronkainen; Helena Autio-Harmainen; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2003-08-19       Impact factor: 3.714

3.  Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats.

Authors:  A Caires; G S Fernandes; A M Leme; B Castino; E A Pessoa; S M Fernandes; C D Fonseca; M F Vattimo; N Schor; F T Borges
Journal:  Braz J Med Biol Res       Date:  2017-12-11       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.